Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology for treating oncogene amplified cancers, announced its participation in the 2024 Guggenheim Global Healthcare Conference. President and CEO Zachary Hornby will participate in a fireside chat on Tuesday, November 12, 2024, at 2:30 p.m. ET in Boston, MA. The session will be available via live and archived webcast in the Investors section of the company's website under 'Events & Presentations'.

11/05/2024 - 07:00 AM

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in the 2024 Guggenheim Global Healthcare Conference.

A fireside chat session is scheduled for Tuesday, November 12, 2024, in Boston, MA, at 2:30 p.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website.

About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapy (ecDTx), BBI-355, which is an oral inhibitor of checkpoint kinase 1 (CHK1) being evaluated in a Phase 1/2 clinical trial in patients with oncogene amplified cancers. Boundless Bio’s second ecDTx, BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) being evaluated in a Phase 1/2 clinical trial in colorectal cancer patients with BRAF^V600E or KRAS^G12C mutations and resistance gene amplifications. Leveraging its Spyglass platform, Boundless Bio has additional program (ecDTx 3) advancing through preclinical development and discovery. Boundless Bio is headquartered in San Diego, CA.
For more information, visit www.boundlessbio.com.

Contacts:
Ben Flaum, Boundless Bio
bflaum@boundlessbio.com

Investors
THRUST Strategic Communications
Renee Leck
renee@thrustsc.com

FAQ

When is Boundless Bio (BOLD) presenting at the 2024 Guggenheim Healthcare Conference?

Boundless Bio will present at the 2024 Guggenheim Global Healthcare Conference on Tuesday, November 12, 2024, at 2:30 p.m. ET in Boston, MA.

How can I watch Boundless Bio's (BOLD) Guggenheim Conference presentation?

The presentation can be accessed via live and archived webcast in the 'Events & Presentations' section of Boundless Bio's website under the Investors tab.